6926 Stock Overview
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shine-On BioMedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$65.00 |
| 52 Week High | NT$80.00 |
| 52 Week Low | NT$58.50 |
| Beta | 0 |
| 1 Month Change | 1.56% |
| 3 Month Change | -1.22% |
| 1 Year Change | -2.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6926 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 1.3% |
| 1Y | -2.3% | -24.2% | 29.2% |
Return vs Industry: 6926 exceeded the TW Biotechs industry which returned -24.2% over the past year.
Return vs Market: 6926 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6926 volatility | |
|---|---|
| 6926 Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6926 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6926's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 19 | n/a | www.shineon-bio.com |
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as SOA101, a dual immune checkpoint inhibitor; and SOA201, a trispecific antibody composed of dual immune cells, as well as exosome anti-cancer drugs, that includes SOB101.
Shine-On BioMedical Co.,Ltd. Fundamentals Summary
| 6926 fundamental statistics | |
|---|---|
| Market cap | NT$3.24b |
| Earnings (TTM) | -NT$37.16m |
| Revenue (TTM) | NT$9.52m |
339.9x
P/S Ratio-87.1x
P/E RatioIs 6926 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6926 income statement (TTM) | |
|---|---|
| Revenue | NT$9.52m |
| Cost of Revenue | NT$2.86m |
| Gross Profit | NT$6.67m |
| Other Expenses | NT$43.83m |
| Earnings | -NT$37.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 70.00% |
| Net Profit Margin | -390.22% |
| Debt/Equity Ratio | 0% |
How did 6926 perform over the long term?
See historical performance and comparison